Phase 1 TP53 Clinical Trials

4 recruitingPhase 1

What is a Phase 1 trial?

Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.

Showing 1–4 of 4 trials

Recruiting

Phase 1

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

Advanced Solid TumorsTP53 Y220C Mutation

PMV Pharmaceuticals, Inc14 enrolled5 locationsNCT07372625

Recruiting

Phase 1

A Phase I First-in-Human Study of GenSci128 in Patients With Solid Tumors Harboring a TP53 Y220C Mutation

Solid Tumors Harboring a TP53 Y220C Mutation

Changchun GeneScience Pharmaceutical Co., Ltd.82 enrolled1 locationNCT06908434

Recruiting

Phase 1Phase 2

Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)

Acute Myeloid LeukemiaTP53

Masonic Cancer Center, University of Minnesota32 enrolled1 locationNCT07008638

Recruiting

Phase 1

Combination of CAR-DC Vaccine and ICIs in Malignant Tumors

Solid Tumor, AdultLymphomaEphA2 Overexpression+4 more

Chinese PLA General Hospital10 enrolled1 locationNCT05631886